In Caraco Pharm.
Labs., Ltd. v. Novo Nordisk A/S , 132 S. Ct. 1670 (April 17, 2012) [ enhanced version available to lexis.com subscribers ],
the Supreme Court unanimously held that a generic drug company may use a
counterclaim provision of the Hatch-Waxman Act to seek correction of an overly
broad use...